William R. Wilson

21.7k total citations · 4 hit papers
377 papers, 16.7k citations indexed

About

William R. Wilson is a scholar working on Molecular Biology, Cancer Research and Organic Chemistry. According to data from OpenAlex, William R. Wilson has authored 377 papers receiving a total of 16.7k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Molecular Biology, 120 papers in Cancer Research and 50 papers in Organic Chemistry. Recurrent topics in William R. Wilson's work include Cancer, Hypoxia, and Metabolism (114 papers), Cancer therapeutics and mechanisms (37 papers) and Nanoplatforms for cancer theranostics (28 papers). William R. Wilson is often cited by papers focused on Cancer, Hypoxia, and Metabolism (114 papers), Cancer therapeutics and mechanisms (37 papers) and Nanoplatforms for cancer theranostics (28 papers). William R. Wilson collaborates with scholars based in New Zealand, United States and Australia. William R. Wilson's co-authors include Michael P. Hay, J. Martin Brown, William A. Denny, Bruce C. Baguley, Brian D. Palmer, Kevin O. Hicks, Zimei Wu, Frederik B. Pruijn, Manju Kanamala and Mimi Yang and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

William R. Wilson

373 papers receiving 16.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting hypoxia in cancer therapy

2011 2.6k citations William R. Wilson, Michael P. Hay profile →
Exploiting tumour hypoxia in cancer treatment

2004 2.3k citations William R. Wilson et al. profile →
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review

2016 830 citations William R. Wilson et al. profile →
Therapeutic targeting of the hypoxic tumour microenvironment

2021 338 citations William R. Wilson et al. profile →

Peers

Countries citing papers authored by William R. Wilson

Since Specialization

Citations

This map shows the geographic impact of William R. Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William R. Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William R. Wilson more than expected).

Fields of papers citing papers by William R. Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William R. Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William R. Wilson. The network helps show where William R. Wilson may publish in the future.

Co-authorship network of co-authors of William R. Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of William R. Wilson. A scholar is included among the top collaborators of William R. Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William R. Wilson. William R. Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Endovascular removal of a large free-floating thrombus of the descending thoracic aorta using the AngioVac system 2024 ·Journal of Vascular Surgery Cases and Innovative Techniques ·William R. Wilson, (unknown), (unknown), (unknown)	1
2	Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation 2023 ·RSC Medicinal Chemistry ·(unknown), (unknown), Robert F. Anderson, William R. Wilson, Michael P. Hay, (unknown)	2
3	Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia 2019 ·International Journal of Radiation Biology ·Tet Woo Lee, (unknown), (unknown), Barbara Lipert, (unknown), Francis W. Hunter, Michael P. Hay, William R. Wilson	37
4	Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors 2019 ·Molecules ·(unknown), (unknown), William R. Wilson, Michael P. Hay	13
5	Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361 2019 ·Biochemical Pharmacology ·(unknown), (unknown), (unknown), (unknown), (unknown), Barbara Lipert, Yongchuan Gu, Francis W. Hunter, William R. Wilson, Michael P. Hay	23
6	Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model 2016 ·Cancer Letters ·(unknown), Stephen M. F. Jamieson, Dongxu Liu, William R. Wilson, Jo K. Perry	31
7	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs 2015 ·Cancer Research ·Francis W. Hunter, Richard J. Young, Zvi Shalev, Ravi N. Vellanki, Jingli Wang, Yongchuan Gu, (unknown), (unknown), Ilan Weinreb, David P. Goldstein, Jason Moffat, Troy Ketela, Kevin R. Brown, Marianne Koritzinsky, Benjamin Solomon, Danny Rischin, William R. Wilson, Bradly G. Wouters	59
8	Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer 2014 ·Molecular Cancer Therapeutics ·Francis W. Hunter, (unknown), (unknown), Susan M. Pullen, William R. Wilson, Jingli Wang	35
9	¹⁸F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model 2013 ·Journal of Nuclear Medicine ·Satish K. Chitneni, Gerald T. Bida, Hong Yuan, Gregory M. Palmer, Michael P. Hay, Thorsten Melcher, William R. Wilson, Michael R. Zalutsky, Mark W. Dewhirst	32
10	The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia 2011 ·Clinical Cancer Research ·Jingli Wang, (unknown), (unknown), (unknown), Michael P. Hay, Kevin O. Hicks, William R. Wilson	55
11	The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3 2010 ·Cancer Research ·Christopher P. Guise, Maria R. Abbattista, Rachelle S. Singleton, (unknown), (unknown), Gabi U. Dachs, Stephen B. Fox, Robert Pollock, (unknown), Parry Guilford, Fernando Doñate, William R. Wilson, Adam V. Patterson	141
12	Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors 2010 ·Clinical Cancer Research ·Kevin O. Hicks, Bronwyn G. Siim, Jagdish K. Jaiswal, Frederik B. Pruijn, (unknown), (unknown), Alison Hogg, H.D. Sarath Liyanage, Mary J. Dorie, Jeremy Brown, William A. Denny, Michael P. Hay, William R. Wilson	103
13	Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N 3 DNA minor groove alkylators 2009 ·Molecular Cancer Therapeutics ·William R. Wilson, Stephen M. Stribbling, Frederik B. Pruijn, Sophie P. Syddall, Adam V. Patterson, H.D. Sarath Liyanage, Eileen Smith, (unknown), Moana Tercel	29
14	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A 2009 ·Molecular Cancer Therapeutics ·Yongchuan Gu, Adam V. Patterson, Graham J. Atwell, Sophia B. Chernikova, Jeremy Brown, Larry H. Thompson, William R. Wilson	52
15	DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity 2009 ·Cancer Research ·Rachelle S. Singleton, Christopher P. Guise, Dianne M. Ferry, Susan M. Pullen, Mary J. Dorie, Jeremy Brown, Adam V. Patterson, William R. Wilson	60
16	Brimonidine 0.1% vs Apraclonidine 0.5% for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty 2008 ·Investigative Ophthalmology & Visual Science ·(unknown), (unknown), (unknown), William R. Wilson	1
17	Effect of cell type and drug lipophilicity on the extravascular transport of small molecule anticancer drugs: tirapazamine analogs 2005 ·Cancer Research ·Kevin O. Hicks, Kashyap Patel, Frederik B. Pruijn, Michael P. Hay, William R. Wilson	1
18	強力なDNAアルキル化剤セコ-CBI-TMIのアミノ類似体の合成及び細胞毒性 1997 ·Bioorganic & Medicinal Chemistry Letters ·Graham J. Atwell, William R. Wilson, (unknown)	1
19	Transnasal septal displacement approach for secondary transsphenoidal pituitary surgery 1992 ·The Laryngoscope ·William R. Wilson, Edward R. Laws	15
20	Some Limits on the Potency of Word-Of-Mouth Information 1989 ·ACR North American Advances ·William R. Wilson, Robert A. Peterson	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact